Epidemiological, Diagnosis, Therapeutic and Evolving Profile of Triple Negative Breast Cancer in Senegal

Abstract

Objective: Describe the epidemiological, diagnostic, therapeutic and evolutionary \nprofile of triple negative breast cancer at the Dakar Cancer Institute in \nSenegal. Patients and Methods: This was a retrospective study between \nJanuary 1, 2011 and December 31, 2014. All patients with a triple negative \nmolecular profile were included. The data were collected from the medical \nrecords of the patients. The data were entered and analyzed with SPSS edition \n16 software under Windows 7. Results: Two hundred and twenty-five patients were selected. The \nmean age was 47.9 ± 12.5 years with extremes of 25 and 90 years. The main \nreason for consultation was dominated by the finding of a breast lump. The mean \nclinical tumor size was 8, 54 cm with a large majority of T3-T4 tumors 26% and 63% respectively, \nlymph node involvement in one hundred and seventy-two cases (76.4%); twenty \neight patients (12.4%) were metastatic from the outset. Non-specific invasive \ncarcinoma was the most common histologic type (78.2%), and more than half of \nthe patients (53.3%) had an aggressive tumor (Scarff-Bloom-Richardson grading \nIII). Neoadjuvant chemotherapy was performed in 65.78% of cases. We noted 27.7% \ntotal response and 41.7% partial response in patients who have received this \nneoadjuvant chemotherapy. The surgery was radical in 77% of cases, conservative \nin 14% and cleanliness surgery for palliative purposes in 9% of cases. Adjuvant \nradiotherapy is performed in 58.6% of operated patients. The mean time to \nfollow-up was 20.63 months with extremes of 1 and 53 months. Overall survival \nwas 69.8% at one year, 41.6% at two years and 25.6% at three years. Conclusion: The descriptive analysis of these results confirms the high frequency of \ntriple-negative breast cancer in Senegal and its poor prognosis.